Nrx pharmaceuticals announces progress on worldwide commercial scale development of zyesami™ (aviptadil)

Radnor, pa., oct. 12, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq:  nrxp ), today announced that a revised investigational new drug module on the manufacturing of zyesami™ (aviptadil) was submitted to the us food and drug administration (fda), containing documentation that confirmed nephron pharmaceuticals, inc. is prepared to supply zyesami on a commercial scale.
NRXP Ratings Summary
NRXP Quant Ranking